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Abstract
Background: The use of analgesic antipyretics (ANAP) in children have long been a matter of controversy. Data on
their practical use on an individual level has, however, been scarce. There are indications of possible effects on
glucose homeostasis and immune function related to the use of ANAP. The aim of this study was to analyze
patterns of analgesic antipyretic use across the clinical centers of The Environmental Determinants of Diabetes in
the Young (TEDDY) prospective cohort study and test if ANAP use was a risk factor for islet autoimmunity.
Methods: Data were collected for 8542 children in the first 2.5 years of life. Incidence was analyzed using logistic
regression with country and first child status as independent variables. Holm’s procedure was used to adjust for
multiplicity of intercountry comparisons. Time to autoantibody seroconversion was analyzed using a Cox
proportional hazards model with cumulative analgesic use as primary time dependent covariate of interest. For
each categorization, a generalized estimating equation (GEE) approach was used.
Results: Higher prevalence of ANAP use was found in the U.S. (95.7%) and Sweden (94.8%) compared to Finland (78.1%)
and Germany (80.2%). First-born children were more commonly given acetaminophen (OR 1.26; 95% CI 1.07,
1.49; p = 0.007) but less commonly Non-Steroidal Anti-inflammatory Drugs (NSAID) (OR 0.86; 95% CI 0.78, 0.95;
p = 0.002). Acetaminophen and NSAID use in the absence of fever and infection was more prevalent in the
U.S. (40.4%; 26.3% of doses) compared to Sweden, Finland and Germany (p < 0.001).
Acetaminophen or NSAID use before age 2.5 years did not predict development of islet autoimmunity by age
6 years (HR 1.02, 95% CI 0.99-1.09; p = 0.27). In a sub-analysis, acetaminophen use in children with fever
weakly predicted development of islet autoimmunity by age 3 years (HR 1.05; 95% CI 1.01-1.09; p = 0.024).
Conclusions: ANAP use in young children is not a risk factor for seroconversion by age 6 years. Use of ANAP
is widespread in young children, and significantly higher in the U.S. compared to other study sites, where use
is common also in absence of fever and infection.
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Background
The administration of analgesic-antipyretic (ANAP)
medications to children has been discussed in the litera-
ture for decades. Surveys of Canadian and American pe-
diatricians reflect the routine use of acetaminophen and
non-steroidal anti-inflammatory drugs (NSAID) for
childhood fever and discomfort [1, 2]. In the 1980s, the
term “fever phobia” was used to describe the parental
pressure facing pediatric practitioners to manage fever
[3]. Parental misconceptions often lead parents to the in-
appropriate management of fever in their children [4]
and parents report the use of antipyretics even when
there was minimal or no fever [5] as parents were fre-
quently concerned with the need to maintain a “normal
temperature” in their ill child [6]. Nevertheless, add-
itional studies are needed to support this as evidence-
based practice [7, 8]. Acetaminophen and NSAID are
used widely in children, but limited data exist regarding
patterns of use in countries beyond the United States,
United Kingdom, France, and Canada [9].
Notably, acetaminophen has been shown to have ef-
fects on glucose homeostasis. High doses have been
shown to induce hyperglycemia [10], whereas low and
chronic doses can lower blood glucose in animal models
[11–13]. Possible effects on asthma risk have also been
investigated [14, 15]. NSAIDs have also been shown to
lower blood glucose [16, 17], but have additional anti-
inflammatory properties that could have an impact on
the process leading up to T1D [18].
The Environmental Determinants of Diabetes in the
Young (TEDDY) Study is an international, multi-center
study designed to identify the environmental triggers of
T1D in genetically at-risk children [19]. The aim of the
current study was to describe the use of ANAP in the
TEDDY study, as well as differences in relation to coun-
try, birth order (first child versus a child with older sib-
lings) and fever status. Specifically, we sought to
examine if the use of ANAP: (1) is associated with risk
for islet autoimmunity (IA), (2) differs between coun-
tries, (3) is given preferentially to first-born children.
Methods
The Environmental Determinants of Diabetes in the
Young (TEDDY) is a prospective cohort study funded by
the National Institutes of Health with the primary goal
to identify environmental causes of type 1 diabetes
(T1D). It includes six clinical research centers - three in
the US: Colorado, Georgia/Florida, Washington and
three in Europe: Finland, Germany, and Sweden. De-
tailed study design and methods have been previously
published [19, 20]. Written informed consents were ob-
tained for all study participants from a parent or primary
caretaker for genetic screening and participation in pro-
spective follow-up. The study was approved by local
Institutional or Ethics Review Boards (Additional file 1),
and is monitored by an External Advisory Board formed
by the National Institutes of Health.
Data collection
The dataset analyzed was the data received by the
TEDDY Data Coordinating Center as of December 31,
2014. The total number of subjects enrolled was 8676.
Analysis was restricted to confirmed HLA eligible sub-
jects and subjects with medication information in the
first 2 years of age. Out of the enrolled subjects, 134
were missing medication data and were excluded from
the analysis. Information regarding first child status was
missing for 919 subjects who were also excluded, leaving
a total of 7623 subjects (Additional file 2).
Study visits were conducted every 3 months with the
first visit occurring between 3 and 4.5 months of age. At
each visit, interviewers recorded the name, reason, start
date and duration of reported medications for the most
recent visit interval. Parents were asked to document
fever as either “Yes” or “No” for every illness entry in a
“TEDDY Book.” The “TEDDY Book” provided written
guidance that “Yes” should only be marked for
temperature equal to or greater than 38 °C or 101 °F.
Approximately 18 months into the study, these choices
were expanded to “Yes – measured,” “Yes – not mea-
sured,” and “No.” The rationale for this change was to
capture all uses of ANAP, even with low-grade fevers.
Each use of an ANAP was defined as an episode. Re-
corded medications were categorized based on active in-
gredient. When analyzing specific substances, all
medications containing that particular substance were
included. Drugs were also defined and grouped as either
analgesic or non-steroidal anti-inflammatory (NSAID)
(Additional file 3). Episodes were described as associated
with infection and/or fever. Infection was defined as ei-
ther an ICD-10 code indicating Infection (Additional file
4) or an acute illness designated as infectious within a
15 day time period of the medication date [21]. Fever
was defined as either an ICD-10 code of fever associated
with the medication or an acute illness associated with
fever within a 15-day time period of the medication
date.
Islet autoimmunity
Blood samples were drawn every 3 months between 3
and 48 months of age, and every 6 months thereafter,
except for autoantibody positive children, who continued
with visits every 3 months. Persistent IA was defined as
positive antibodies to insulin (IAA), glutamic acid de-
carboxylase (GAD65), or insulinoma-associated antigen
2 (IA-2), each analyzed by radiobinding assay [22, 23],
on at least 2 consecutive study visits. Two central auto-
antibody laboratories were used; one in the U.S. (Barbara
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Davis Center for Childhood Diabetes at the University of
Colorado) and one in Europe (University of Bristol). All
positive islet autoantibodies and 5% of negative islet
autoantibodies were confirmed in both central autoanti-
body laboratories. Both laboratories have previously
demonstrated high sensitivity, specificity [24] and con-
cordance. Positive results in the child that were deemed
to be due to maternal IgG transmission were excluded
from the IA-positive group.
Statistical methods
A Cox proportional hazards model was used to assess
the impact of ANAP use in the first 90, 180, 365 days of
age and 2.5 years of age in the risk of positive autoanti-
bodies through 6 years of age. The number of infections
early in life was included as a time dependent covariate
[25]. Country was included as a stratification factor in
the proportional hazards analyses. Additional covariates
included in the model were first-degree relative [26],
HLA [27], gender, ever breastfed [28, 29], probiotic use
prior to 3 months of age [30], and eight different previ-
ously identified single nucleotide polymorphisms [31].
The primary variable of interest was cumulative ANAP
use through 2.5 years of life as a time dependent covari-
ate. Included covariates can be seen in Table 1.
The statistical analysis for the number of episodes per
year and duration per year excluded subjects for which
the first child status was missing. Subjects with a missing
duration for a specific analgesic were excluded from the
analysis for that analgesic. The statistical analysis of total
duration per year was based on log-transformed data to
better satisfy the assumptions of the linear models.
Subject incidence was analyzed using logistic regression
with country and first child status as independent vari-
ables in the model. In both the binary and continuous
analyses, pairwise comparisons between countries were
conducted using Holm’s procedure to adjust for the multi-
plicity of comparisons. Each specific episode of ANAP
usage was classified by concurrent fever (yes/no) or infec-
tion (yes/no). Episodes were categorized as associated with
Fever, Infection, both Fever and Infection, or neither fever
nor infection. For each categorization, a generalized esti-
mating equation (GEE) was used for analysis with country
and first child as independent variables in the model. An
ignorable working matrix was assumed for the GEE ana-
lysis with the empirical sandwich estimate used for the
standard errors. Pair-wise comparisons across countries
were conducted using Holm’s procedure from the GEE
analyses. Analyses on the episode level excluded subjects
who reported no episodes.
Table 1 Covariates included in the Cox proportionate hazards analysis of time to persistent confirmed autoantibody positivity
Fixed Covariates Hazard Ratio (95% CI) Wald test p-valuea
First-Degree Relative (Ref = No) 2.51 (2.06, 3.30) <0.001
HLA (Ref = DR3/DR4)
DR4/DR4 0.69 (0.54, 0.88) 0.003
DR4/DR8 0.70 (0.54, 0.91) 0.008
DR3/DR3 0.46 (0.35, 0.60) <0.001
All Others 0.46 (0.29, 0.72) <0.001
Gender (Ref = male) 0.77 (0.65, 0.92) 0.003
SNP
RS1004446_a 0.84 (0.74, 0.96) 0.010
RS10517086_a 1.14 (1.00, 1.31) 0.050
RS12708716_g 0.87 (0.76, 0.99) 0.034
RS2292239_a 1.24 (1.09, 1.41) <0.001
RS2476601_a 1.55 (1.31, 1.83) <0.001
RS2816316_c 1.07 (0.91, 1.25) 0.429
RS3184504_a 1.33 (1.17, 1.50) <0.001
RS4948088_a 0.74 (0.53, 1.04) 0.086
Ever Breastfed (Ref = No) 1.96 (1.01, 3.81) 0.042
Probiotics <3 Mo Age (Ref = No) 0.72 (0.55, 0.94) 0.015
Time Dependent Covariates
Cumulative Number of Infections 1.02 (0.99, 1.03) 0.407
Cumulative Weeks Analgesic Use 1.02 (0.99, 1.04) 0.269
Number of persistent confirmed cases = 511
aHo: Hazard Ratio = 1
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Statistical analysis was performed using SAS version
9.3 (SAS Institute Inc., Cary, NC, U.S.A).
Results
Use of ANAP below the age of 2.5 years
The use of both acetaminophen and NSAIDs were very
common in the study population. In the total cohort,
87.8% of children reported the use of acetaminophen
and 45.4% of NSAIDs before the age of 2.5 years. The
mean number of treatment episodes per year was
3.6 ± 2.1 and mean duration of treatment 8.5 ± 10.8 days
per year in the total cohort (Fig. 1a–c).
Acetaminophen use
Swedish parents reported a significantly higher preva-
lence of acetaminophen use (94.5%), followed by U.S.
(93.7%), Finnish (73.9%), and German parents (70.1%).
Prevalence differed between all countries (Finland vs.
Germany: p = 0.035, all other p < 0.001). U.S. parents re-
ported the highest number of treatment episodes per
year and highest total duration of treatment per year
(mean 4.0 ± 2.3 episodes; mean 9.8 ± 13.5 days),
followed by Swedish (mean 3.6 ± 2.1 episodes; mean
8.4 ± 8.6 days), Finnish (mean 2.7 ± 1.9 episodes; mean
6.8 ± 6.4 days), and German parents (mean 2.5 ± 1.6 epi-
sodes; mean 4.7 ± 3.7 days). All country differences, ac-
cording to number of treatment episodes, were
statistically significant (Finland vs. Germany: p = 0.014,
all others p < 0.001) (Fig. 1). Children born as the first
child in the family had more often been given acet-
aminophen during their first 2.5 years of life compared
to children with older siblings (OR 1.26; 95% CI 1.07,
1.49; p = 0.007). The number of episodes of treatment
with acetaminophen was also higher (difference in least
square means 0.15; 95% CI 0.05, 9.24; p = 0.003). No dif-
ference could be seen regarding the number of days
treated (difference in least square means 0.11; 95% CI
-0.38, 0.60; p = 0.111).
NSAID use
The highest prevalence of NSAID use was reported
by U.S. parents (58.3%), followed by German (44.1%),
Finnish (42.3%), and Swedish parents (29.0%). All
country differences, except between Finland and
Germany, were statistically significant (Finland vs.
Germany: p = 0.177, all others p < 0.001). U.S. par-
ents reported the highest number of treatment epi-
sodes with NSAID per year (mean 2.1 ± 1.4 episodes;
mean 6.8 ± 11.2 days), followed by Swedish, Finnish,
and German parents (mean 1.6 ± 1.2; mean 1.6 ± 1.2;
mean 1.6 ± 1.1) Total duration of treatment was
highest in the U.S. (mean 6.8 ± 11.2 days), followed
by Finland (mean 5.3 ± 9.3 days), Germany (mean
5.2 ± 17.2 days), and Sweden (mean 4.9 ± 4.8 days).
Both the mean number of treatment episodes and
mean total duration of treatment were significantly
higher in the U.S. compared to the other countries
(p < 0.001). No other significant country differences
could be seen (Fig. 1). The prevalence of NSAID use
during the first 2.5 years of life were lower in first-
born children (OR 0.86; 95% CI 0.78, 0.95; p = 0.002)
and they were also treated fewer times (difference in
least square means −0.14; 95% CI -0.22, −0.05;
p = 0.001). No differences could be seen regarding
the number of days treated (difference in least square
means −0.22; 95% CI -0.92, 0.48; p = 0.143).
A
B
C
Fig. 1 Use of ANAP below 2,5 years of age. *:p < 0.05, n.s.: non
significant. All significances corrected for multiple comparisons using
Holm procedure. a Prevalence of analgesic/antipyretic use. b
Treatment episodes per year. c Duration of medication use per year
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Differences in use for febrile/infectious episodes and
noninfectious use
In the total cohort, 74.1% of acetaminophen use and
82.0% of NSAID use was given in conjunction with ei-
ther fever, infection or both, with 43.8% acetaminophen
use and 51.0% NSAID episodes being combined fever
and infection. U.S. parents reported a significantly higher
proportion of doses given without fever or infection for
both acetaminophen (40.4%) and NSAID (26.3%) com-
pared to the other three countries (p < 0.001). Acet-
aminophen use in feverish infectious episodes had the
highest proportion among German and Swedish children
(68.5% and 63.2%;), followed by Finland with 57.9% and
the U.S. with 23.5% (all p-values for differences between
countries were p < 0.001, except between Germany and
Swedenwas p = 0.003).
For NSAID use without fever or infection, the U.S.
parents reported the highest proportion (26.3%),
followed by Finland (7.7%), Germany (5.9%), and Sweden
(3.7%) (difference between Finland and Sweden
p = 0.006; between Germany and Sweden p = 0.01; all
others p < 0.001) (Fig. 2, Table 2).
Islet autoimmunity
Hazard ratios for islet autoimmunity were estimated for
cumulative use of acetaminophen and NSAID with or
without concomitant fever and for a joint variable of cu-
mulative total ANAP use with or without fever. A sig-
nificant hazard was only found for use of acetaminophen
in the presence of fever for islet autoimmunity at age 3
years (HR 1.05; 95% CI 1.01-1.09; p = 0.024). The hazard
was not significant for islet autoimmunity at 6 years of
age (p = 0.193).
Separate analysis of exposure before 90, 180 and
365 days of life found a significant hazard for serocon-
version at age 3 years (HR 1.06; 95% CI 1.00-1.12;
p = 0.011) for use of acetaminophen with concurrent
fever before 1 year of age, but not before 90 or 180 days
of life (p = 0.91 and p = 0.54, respectively). No other sig-
nificant hazards could be seen for treatment with acet-
aminophen or NSAID in the presence or absence of
fever (Table 3).
Discussion
In this study, we investigated the use of ANAP in chil-
dren below the age of 2.5 years, and the impact of such
use on the development of islet autoimmunity before 6
years of age in the large, longitudinal, international
TEDDY cohort.
The widespread use of acetaminophen among young
children has been of interest due not only to possible
side effects, but also possible immunological effects.
Several papers have investigated the impact on im-
mune response and the development of autoimmunity
[11, 12, 32, 33]. The data on childhood asthma is
conflicting, with some studies showing an increased
risk and others showing none [14, 15, 34]. The use of
prophylactic acetaminophen in conjunction with
childhood vaccinations has also shown possible effects
on antibody responses [1, 7, 35]. In this study, we
found a significant but weak increased hazard ratio
associated with the use of acetaminophen and con-
comitant fever before the age of 2.5 years and persist-
ent confirmed islet autoimmunity at age 3 years.
However, this effect was not seen with islet auto-
immunity at age 6 years or if acetaminophen was
used for other reasons. It is therefore unlikely, al-
though possible, that this is a true effect. The type of
infection causing the fever may be a confounding fac-
tor. No such effect was seen with the use of NSAIDs
or the combination of acetaminophen and NSAIDs,
either when given with or without fever.
The use of acetaminophen and NSAIDs for the treat-
ment of children has been previously described from a
medical standpoint [36, 37]. On the other hand, very lit-
tle has been described regarding practical use in the
pediatric population. This analysis within a large inter-
national cohort provides some of the first data regarding
pediatric use of ANAP. As expected,the majority of
treatment episodes for this young cohort were in con-
junction with fever and/or infection. It is worth men-
tioning that there are significant differences between the
TEDDY countries regarding the use of both acetamino-
phen and NSAIDs. The U.S. stands out for both greater
prevalence of use and greater number of episodes of
treatment per year, followed closely by Sweden in
regards to acetaminophen use. U.S. parents were also
just as likely to report using these medications during
episodes associated with infection than non-infectious
episodes. Additionally, they were more likely to use
ANAP when there was no associated fever. It may be a
common practice of American physicians to prescribe a
Fig. 2 Fraction of treatment without fever and infection. *:p < 0.05,
n.s.: non-significant. All significances corrected for multiple comparisons
using Holm procedure
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combination therapy approach to the use of analgesics
and antipyretics forthe sustained management of fever.
However, parents may then assume that even prophylac-
tic use should be a combination therapy.
We also found that first-born children were preferen-
tially given acetaminophen, both in prevalence of use
and in the higher number of treatment episodes than for
their younger siblings. The inverse relationship was ob-
served for NSAID use, in which both the prevalence and
number of treatment episodes were lower for first-born
children. We can only speculate on the possible
rationale behind this finding since, to our knowledge, no
earlier study has presented similar data. It is possible
that acetaminophen is perceived by first-time parents as
a better tolerated treatmentthan NSAIDS, a perception
that fades by the time younger siblings require
treatment.
Country-specific differences in the use of analge-
sics may be culturally influenced. The lower inci-
dence of use of all standard analgesics in Germany
could reflect the prevalence of Complimentary Alter-
native Medicine (CAM) in this country. According
Table 2 Summary of treatment episodes associated with fever and/or infection
US Finland Germany Sweden Total Cohort Country differences
U-F U-G U-S F-G F-S G-S
Total episodes n 25,340 7427 2091 17,285 52,643
Acetaminophen Fever and infection n 4272 2907 983 9224 17,386 <0.001 <0.001 <0.001 <0.001 <0.001 0.003
Fever or infection 6557 1277 311 3421 12,066
No fever and no infection n 7348 841 141 1953 10,283 <0.001 <0.001 <0.001 <0.001 0.006 0.01
NSAID Fever and infection n 2680 1273 477 1572 6002 <0.001 <0.001 <0.001 <0.001 <0.001 0.024
Fever or infection n 2472 717 125 330 3644
No fever and no infection n 1841 167 38 74 2120 <0.001 <0.001 <0.001 0.174 <0.001 0.041
Country differences: U = US, G = Germany, F = Finland, S = Sweden, Country differences described as p-value for difference between the respective countries
Table 3 Hazard ratios for seroconversion to persistent islet autoimmunity at 3 and 6 years of age for analgesic variables of interest
Analgesic Variable Exposed
subjects n
(%)
3 Year Analysis 6 Year Analysis
398 antibody + subjects 511 antibody + subjects
HR (95% CI) p-value HR (95% CI) p-value
Acetaminophen, any exposure 7496 (87.8%) 1.01 (0.97, 1.05) 0.603 1.01 (0.98, 1.05) 0.576
Acetaminophen with fever + infection 5179 (60.6%) 1.05 (1.01, 1.09) 0.022 1.03 (0.99, 1.08) 0.189
Exposed <90 days of life 220 (2.6%) 0.97 (0.59, 1.61) 0.914 1.00 (0.68, 1.46) 0.986
Exposed <180 days of life 1519 (17.8%) 1.07 (0.87, 1.32) 0.542 1.06 (0.88, 1.27) 0.527
Exposed <365 days of life 3795 (44.4%) 1.06 (1.00, 1.12) 0.011 1.05 (0.99, 1.11) 0.101
Acetaminophen without fever or infection 5941 (69.6%) 1.02 (0.98, 1.06) 0.346 1.01 (0.96, 1.05) 0.769
Exposed <90 days of life 4016 (47.0%) 1.00 (0.90, 1.11) 0.994 0.99 (0.85, 1.14) 0.837
Exposed <180 days of life 4597 (53.8%) 0.98 (0.84, 1.14) 0.814 0.97 (0.84, 1.13) 0.729
Exposed <365 days of life 5310 (62.2%) 1.03 (0.99, 1.06) 0.114 1.02 (0.99, 1.06) 0.228
NSAID, any exposure 3874 (45.4%) 1.01 (0.97, 1.05) 0.753 1.01 (0.97, 1.04) 0.763
NSAID with fever + infection 2652 (31.0%) 1.01 (0.97, 1.05) 0.673 1.01 (0.98, 1.05) 0.459
Exposed <90 days of life 22 (0.3%) 1.01 (0.92, 1.10) 0.897 1.00 (0.92, 1.09) 0.960
Exposed <180 days of life 223 (2.6%) 0.99 (0.88, 1.11) 0.822 1.00 (0.94, 1.07) 0.927
Exposed <365 days of life 1318 (15.4%) 1.01 (0.97, 1.06) 0.530 1.02 (0.98, 1.05) 0.378
NSAID without fever or infection 1955 (22.9%) 1.00 (0.96, 1.05) 0.856 1.01 (0.97, 1.05) 0.623
Exposed <90 days of life 222 (2.6%) 1.00 (0.88, 1.12) 0.943 0.99 (0.88, 1.12) 0.874
Exposed <180 days of life 458 (5.4%) 0.99 (0.88, 1.11) 0.815 1.00 (0.94, 1.07) 0.956
Exposed <365 days of life 1120 (13.1%) 1.01 (0.96, 1.06) 0.824 1.01 (0.97, 1.05) 0.638
Any analgesic, any exposure 7744 (91%) 1.02 (0.99, 1.05) 0.130 1.02 (0.99, 1.04) 0.267
Any analgesic with fever + infection 5699 (67%) 1.06 (0.97, 1.15) 0.219 1.02 (0.94, 1.10) 0.667
Each hazard ratio is calculated from a Cox proportional hazards model with the analgesic variable and covariates indicated in text
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to a cross-sectional survey of German physicians in
2007, more than two-thirds of patients in Germany use
CAM provided either by physicians or non-medical practi-
tioners (“Heilpraktiker”) [38]. In 2007, only 40% of adults
in the U.S. had used CAM therapy in the past 12 months.
Children in the U.S. whose parents used CAM were almost
five times as likely (23.9%) to use CAM than children
whose parent did not use CAM (5.1%) [39]. The reasons
underlying greater use of acetaminophen among Swedish
parents is more unclear but may be the result of acet-
aminophen being widely available and perceived as safe
and effective.
The TEDDY study is one of the largest longitudinal
pediatric cohorts studied. The data analyzed herein
has been collected from parent reports given in writ-
ing and after discussion with a TEDDY nurse. For
participating children, missing data is uncommon.
Follow-up is continuous from age 3 months which
minimizes recall bias. The possibility to adjust for
confounding factors in the statistical analysis is great
due to the availability of comprehensive data on the
child’s living conditions. All previously described risk
factors for T1D and islet autoimmunity are also en-
tered into the statistical analysis of the effect of anal-
gesics on islet autoimmunity.
The limitations of this study include our reliance
on parent-reported symptoms and dosages of ANAP.
The size of the cohort also makes it challenging to
confirm diagnoses and treatment plans via patient re-
cords. Notably, most of the reported infections were
presumed to be viral infections for which no medical
advice had been sought. In addition, the widespread
use of ANAP in this age group poses a significant
statistical problem since the exposed group widely
surpasses the non-exposed group. Even with the large
sample size, the resulting correlation between IA and
acetaminophen in combination with fever must there-
fore be interpreted with caution.
Conclusions
In conclusion, the use of ANAP to treat fever and
infection is widespread in the TEDDY cohort but
shows significant differences depending on study site.
The prevalence of use of both acetaminophen and
NSAIDs are highest in the U.S. and lowest in
Finland and Germany. Use of both NSAIDs and
acetaminophen for non-infectious purposes are sig-
nificantly more common among children in the U.S.
compared to those in Europe. No convincing effect
on risk for autoimmunity can be seen in the analysis
except for a small effect by acetaminophen in com-
bination with fever, and then only for autoimmunity
at 3 years of age.
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